⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23561574 | 0.91 | — | — | |
| SCHEMBL20445430 | 0.91 | — | — | |
| SCHEMBL21694941 | 0.90 | FBP1 (0.35) | — | |
| SCHEMBL23188273 | 0.88 | — | — | |
| SCHEMBL23593961 | 0.85 | — | — | |
| SCHEMBL20649469 | 0.84 | — | — | |
| SCHEMBL16232542 | 0.83 | P2RY14 (0.33) | — | |
| SCHEMBL16904631 | 0.81 | FBP1 (0.32) | — | |
| SCHEMBL23476094 | 0.80 | FBP1 (0.35) | — | |
| SCHEMBL15935859 | 0.80 | FBP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11236338-B2 | Antisense-induced exon2 inclusion in acid alpha-glucosidase | SAREPTA THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210220386-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-11060089-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210187003-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210161922-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-06-03 | — | — | US | disclosed |
| US-10888578-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200377886-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-10849917-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10822608-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190284555-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-20190262375-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190201425-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-04 | — | — | US | disclosed |
| US-20190127735-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-28 | — | — | US | disclosed |